Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Human Genome Sciences Inc.105 enrolled

Overview

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

105

Conditions

Multiple Myeloma

Interventions

MapatumumabBIOLOGICAL

10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

MapatumumabBIOLOGICAL

20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

BortezomibDRUG

1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with multiple myeloma that is refractory or has relapsed after treatment * Measurable serum and/or urine M-protein * Failed 1 or 2 prior therapies for multiple myeloma * 18 years of age or older Exclusion Criteria: * Received more than 2 prior therapies for multiple myeloma. * Previous cancer therapies (chemotherapy, biologic therapy, radiation therapy or immunosuppressants) within the last 3 weeks * Received monoclonal antibodies within the last 3 weeks (chimeric or murine) or 8 weeks (human or humanized) * Received investigational (not yet approved by a regulatory authority) agent to treat multiple myeloma within the last 4 weeks * Subjects who received a stem cell transplant using cells from themselves in the past 16 weeks * Subjects who received a stem cell transplant using cells from another individual * Previously treated with bortezomib or mapatumumab * Known HIV, hepatitis-B, hepatitis-C, or hepatitis A infection * Infection requiring antibiotics or hospitalization within the last 2 weeks * Major surgery within the last 4 weeks * Diagnosis with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) * History of other cancers within the past 5 years * Pregnant or breast-feeding women

Locations (20)

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Outcomes

Primary Outcomes

To evaluate disease response to mapatumumab in combination with bortezomib and bortezomib alone

Time frame: 17 cycles (up to a year)

Secondary Outcomes

To evaluate the safety, including the frequency and severity of adverse events and laboratory abnormalities, of mapatumumab in combination with bortezomib and bortezomib alone throughout the study period

Time frame: 17 cycles (up to a year)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.